A decade of progress in myelodysplastic syndrome with chromosome 5q deletion

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

(2016) Lionel Ades et al.   HAEMATOLOGICA

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations

(2016) Christian Scharenberg et al.   HAEMATOLOGICA

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)

(2016) M Mossner et al.   LEUKEMIA

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase

(2016) Georg Petzold et al.   NATURE

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

(2016) Jing Fang et al.   NATURE MEDICINE

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

(2016) Lionel Ades et al.   HAEMATOLOGICA

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations

(2016) Christian Scharenberg et al.   HAEMATOLOGICA

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q

(2015) M Heuser et al.   LEUKEMIA

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

(2015) Jan Krönke et al.   NATURE

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

(2014) Joaquín Sánchez-García et al.   BRITISH JOURNAL OF HAEMATOLOGY

Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS

(2014) Rebekka K. Schneider et al.   CANCER CELL

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

(2014) L. Saft et al.   HAEMATOLOGICA

Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia

(2014) Marcus Järås et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

(2014) Eric S. Fischer et al.   NATURE

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

(2014) Terrence N. Wong et al.   NATURE

Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs

(2014) Philip P Chamberlain et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Applying Synthetic Lethality for the Selective Targeting of Cancer

(2014) Donal P. McLornan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)

(2014) M A Sekeres et al.   Blood Cancer Journal

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

(2013) Aristoteles Giagounidis et al.   ANNALS OF HEMATOLOGY

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations

(2013) Mar Mallo et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

TP53mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

(2013) Austin G. Kulasekararaj et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes

(2013) M. Fernandez-Mercado et al.   HAEMATOLOGICA

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia

(2013) A Pellagatti et al.   LEUKEMIA

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

(2013) A F List et al.   LEUKEMIA

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Cancer Vulnerabilities Unveiled by Genomic Loss

(2012) Deepak Nijhawan et al.   CELL

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

(2012) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

(2012) U Germing et al.   LEUKEMIA

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

(2012) A Kuendgen et al.   LEUKEMIA

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

(2011) M. A. Sekeres et al.   BLOOD

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

(2011) L. Mollgard et al.   HAEMATOLOGICA

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

(2011) L. Ades et al.   HAEMATOLOGICA

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

(2011) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

(2010) M Mallo et al.   LEUKEMIA

Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission

(2010) Ramin Tehranchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

RING Domain E3 Ubiquitin Ligases

(2009) Raymond J. Deshaies et al.   Annual Review of Biochemistry

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

(2008) L. Ades et al.   BLOOD

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

(2008) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

(2008) C. Kelaidi et al.   LEUKEMIA RESEARCH